Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis. (July 2018)

• Record Type: Journal Article
• Authors: Criscitiello, Carmen; Golshan, Mehra; Barry, William T.; Viale, Giulia; Wong, Stephanie; Santangelo, Michele; Curigliano, Giuseppe
• Is Part Of: European journal of cancer. Volume 97(2018)
• Page Start: 1
• Page End: 6
• Publication Date: 2018-07
• Subjects: Neoadjuvant therapy -- Breast cancer -- Mastectomy -- Quadrantectomy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2018.03.023
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Purpose: We conducted a meta-analysis of randomised trials evaluating pathological complete response (pCR) and surgical outcomes after neoadjuvant systemic therapy (NST) in patients with early breast cancer (EBC). Patients and methods: The primary outcome was breast-conserving surgery (BCT) rate. Secondary outcomes were pCR rate and association to BCT. Meta-analyses were performed using random effects models that use inverse-variance weighting for each treatment arm based on evaluable patients. Point estimates are reported with 95% confidence interval (CI), and p < 0.05 was considered statistically significant. Results: Thirty-six studies were identified (N = 12, 311 patients). We selected for the analysis 16 of 36 studies reporting both pCR and BCT for at least one treatment arm. Arms per study ranged from one to six; 42 independent units were available to evaluate the association between pCR and BCT. BCT rate ranged 5–76% across arms with an average BCT of 57% (95% CI 52–62%). Significant heterogeneity was observed among the trials (Cochrane Q = 787, p < 0.001, I 2 = 97%). In the meta-regression model, BCT rates were not significantly associated with year of first patient-in (p = 0.89), grade (p = 0.93) and hormone-receptor status (p = 0.39). Clinical N-stage (p = 0.01) and human epidermal growth factor receptor (HER2) status (p = 0.03) were significantly associated with BCT. pCR rate ranged 3–60% across studies. The average pCR across all study arms was 24% (95% CI 19–29%). No association was observed between pCR rate in a study arm and the resulting BCT rate in a univariate model (p = 0.34) nor after adjusting for HER2 and clinical nodal status (p = 0.82). In the subset of 14 multi-arm studies, no significant association was seen between the differences in pCR and BCT between treatment arms (p = 0.27). Conclusions: pCR does not increase BCT in patients receiving NST for EBC. Highlights: Neoadjuvant systemic therapy (NST) achieves equivalent local recurrence, disease-free and overall survival outcomes as compared with adjuvant therapy in early breast cancer (EBC). We conducted a meta-analysis of randomised trials evaluating pathological complete response (pCR) and surgical outcomes after NST in patients with EBC. pCR does not increase BCT in patients receiving NST for EBC.